To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 252
- Registration Number
- NCT04675931
- Locations
- 🇺🇬
Novartis Investigative Site, Tororo, Uganda
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 98
- Registration Number
- NCT04667949
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT04666259
- Locations
- 🇺🇸
Univ of TX MD Anderson Cancer Cntr ., Houston, Texas, United States
🇺🇸Uni of Cincinnati Medical Center ., Cincinnati, Ohio, United States
🇺🇸Oncology Hematology Care Inc ., Cincinnati, Ohio, United States
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT04666272
- Locations
- 🇨🇳
Novartis Investigative Site, Wuhan, China
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT04667117
- Locations
- 🇺🇸
The MS Center for Innovation in Care, Saint Louis, Missouri, United States
🇺🇸Hope Research Institute Center Neurology and Spine, Phoenix, Arizona, United States
🇺🇸Infinity Clinical Research LLC, Hollywood, Florida, United States
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
- Conditions
- HypercholesterolemiaHeterozygous Familial Hypercholesterolemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 312
- Registration Number
- NCT04666298
- Locations
- 🇯🇵
Novartis Investigative Site, Saga, Japan
A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT04665154
- Locations
- 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT04662931
- Locations
- 🇮🇳
Novartis Investigative Site, Kolkata, West Bengal, India
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 494
- Registration Number
- NCT04662944
- Locations
- 🇪🇸
Novartis Investigative Site, Leon, Spain
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
- Conditions
- Familial Hypercholesterolemia - Homozygous
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT04659863
- Locations
- 🇺🇸
Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States
🇱🇧Hotel Dieu de France Hospital, Ashrafieh, Lebanon
🇹🇷Novartis Investigative Site, Izmir, Turkey